News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
145
Sources here
16
Companies here
2
Search results Stored financial headlines

Active search

145 matching headlines

Ticker or company: PTCMain company stories
Clear
Latest

MarketBeat Earnings

333,702 Shares in PTC Inc. $PTC Purchased by SCS Capital Management LLC

SCS Capital Management LLC recently acquired 333,702 shares of PTC Inc. (NASDAQ:PTC), valued at approximately $37.9 million, making it their 20th largest holding. This purchase gives SCS Capital Management LLC about a 0.31% stake in the technology company. Despite PTC slightly beating EPS estimates with $1.58, its revenue of $600.05 million fell short of expectations and represented a …

Main company 🇺🇸 United States
Read at MarketBeat
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Moomoo Guidance Main company 🇺🇸 United States

PTC Therapeutics Is Maintained at Overweight by Barclays

Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT

Walleye Capital LLC has acquired a new position in PTC Therapeutics, Inc., purchasing 19,522 shares valued at approximately $1.59 million during the second quarter. Several other institutional investors also increased their holdings in the biopharmaceutical company, which has an average analyst rating of "Moderate …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

MarketBeat Earnings Main company 🇺🇸 United States

PTC Inc. $PTC Shares Purchased by Meyer Handelman Co.

Meyer Handelman Co. significantly increased its stake in PTC Inc. (NASDAQ:PTC) during the second quarter, purchasing an additional 44,340 shares to bring its total holdings to 92,884 shares valued at $10.55 million. This purchase reflects continued institutional interest, as institutional investors and hedge funds …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

PTCT Maintained by Barclays -- Price Target Raised to $122

Barclays has maintained an "Overweight" rating for PTC Therapeutics (PTCT) and increased its price target to $122.00 from $120.00. Despite this positive analyst outlook, GuruFocus indicates the stock is significantly overvalued at $71.52 against a GF Value of $37.55, with a mixed GF Score …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

T. Rowe Price Investment Management (PTC) discloses 13.1M-share position in PTC Inc.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G/A, disclosing a beneficial ownership of 13,063,201 shares of PTC Inc. common stock, which represents an 11.3% stake in the company. The filing indicates that T. Rowe Price holds sole voting power over 12,568,696 …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioPharma Dive Deals and strategy Main company 🇺🇸 United States

PTC takes a chance on Sangamo’s Fabry disease gene therapy

PTC Therapeutics has acquired an experimental gene therapy for Fabry disease, ST-920, from the bankrupt Sangamo Therapeutics for up to $211 million. Analysts view this as a risky but potentially high-reward move, as the treatment is nearing FDA approval and could offer a superior …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Earnings Main company 🇺🇸 United States

A Look at PTC Inc (PTC) After 4.0% Gain -- GF Value $220.51 vs P

PTC Inc (PTC) shares rose 4.0% today to $153.89, which is 30.2% undervalued compared to its GF Value of $220.51. The company has a strong GF Score of 79/100, indicating robust fundamentals, particularly in profitability and growth, despite lower valuation and momentum scores. While …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MedCity News Deals and strategy Main company 🇺🇸 United States

PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy

PTC Therapeutics has won a bankruptcy auction for Sangamo Therapeutics' gene therapy candidate, isaralgagene civaparvovec (ST-920), for Fabry disease, with a bid of $111 million upfront and up to $100 million in milestone payments. This acquisition expands PTC's rare disease pipeline, bringing a therapy …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketWatch Market update Main company 🇺🇸 United States

PTC Inc. stock outperforms competitors on strong trading day

PTC Inc. (PTC) stock gained 3.99% to $153.89 on Thursday, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average. This rise ended a two-day losing streak for the company's shares. The strong performance occurred on a positive trading day …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TipRanks Deals and strategy Main company 🇺🇸 United States

PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy

PTC Therapeutics (PTCT) is acquiring ST-920, a BLA-stage Fabry gene therapy, from Sangamo Therapeutics for $111 million upfront and up to $100 million in milestones. This acquisition aims to expand PTC's rare disease portfolio and facilitate accelerated FDA approval by late 2026, with a …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Business Journals Deals and strategy Main company 🇺🇸 United States

Bankrupt Sangamo scores at least $163 million in asset sale, which had two big winners

Bankrupt Sangamo Therapeutics secured at least $163 million from an asset sale, with Eli Lilly and PTC Therapeutics emerging as the primary buyers. This auction marks a crucial step in winding down Sangamo's 31-year history, a company that spent $1.7 billion on drug technologies …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketWatch Market update Main company 🇺🇸 United States

PTC Inc. stock underperforms Wednesday when compared to competitors

PTC Inc. (PTC) stock declined by 1.63% to $147.99 on Wednesday, marking its second consecutive day of losses. This underperformance occurred despite a mixed trading session where the S&P 500 Index rose 0.26% and the Dow Jones Industrial Average fell 0.04%. The article highlights …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Guidance Main company 🇺🇸 United States

Avoiding Lag: Real-Time Signals in (PTC) Movement

This article analyzes real-time signals for PTC Inc. (NYSE: PTC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies no clear price positioning signal and compelling upside potential due to the absence of resistance levels above the current price. The …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

How Ptc Therapeutics Inc. (PTCT) Affects Rotational Strategy Timing

This article analyzes Ptc Therapeutics Inc. (PTCT) using AI models to provide institutional trading strategies. It highlights a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias, and details specific position, momentum breakout, and risk hedging strategies with entry zones, …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Earnings Main company 🇺🇸 United States

Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment

PTC Therapeutics (PTCT) saw its stock rise by 6.7% following a strong second quarter in 2026, reporting US$360.52 million in revenue and US$83.5 million in net income. The company also raised its full-year 2026 revenue outlook to between US$1.18 billion and US$1.28 billion and …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

PTC Inc. (PTC) Stock Forecasts

This article provides a stock forecast for PTC Inc. (PTC), highlighting its position as a global technology company offering CAD, PLM, and AR solutions to industrial manufacturers. A Morningstar analyst report, dated August 10, 2026, details PTC's earnings, emphasizing how resources from divestitures support …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Earnings Main company 🇺🇸 United States

Is PTC Therapeutics (PTCT) Undervalued As Profit And Revenue Guidance Jumped?

PTC Therapeutics reported a significant shift from a loss to a net income of US$83.5 million in Q2 2026 and raised its full-year revenue guidance to US$1.18b-US$1.28b. Despite a recent share price increase of 9.56% over the past week, the stock is considered 23% …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Assenagon Asset Management S.A. Has $25.56 Million Stake in PTC Inc. $PTC

Assenagon Asset Management S.A. significantly increased its stake in PTC Inc. by 104.5% in the second quarter, now holding 224,989 shares valued at $25.56 million. Other institutional investors also modified their holdings, with Rakuten Securities Inc. notably lifting its position by 2,725%. Analysts currently …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Bank of America Corp DE Sells 39,720 Shares of PTC Inc. $PTC

Bank of America Corp DE reduced its stake in PTC Inc. by 5.7%, selling 39,720 shares and retaining 652,179 shares valued at approximately $92.9 million. Institutional investors hold 95.14% of PTC's stock. The company recently reported quarterly EPS of $1.58, beating estimates, but revenue …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

ETFs Investing in PTC Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold PTC Inc. stocks, sorted by market value. It details various ETFs from different issuers, including Vanguard, BlackRock, and State Street, along with their market value, weight of PTC Inc. stock, expense …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

PTC (PTC) Rolls Out AI Tools Across ALM And PLM Workflows

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. PTC (NasdaqGS: PTC) announced new AI-driven capabilities and workflow connectivity features across its ALM portfolio and Arena PLM platform. The updates target engineering efficiency, tighter …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Has PTC (PTC) Fallen Enough To Look Reasonable?

PTC stock has dropped 28.1% over the past year, making its valuation appear reasonable. Simply Wall St's analysis suggests PTC is undervalued in 5 out of 6 valuation tests, with a P/E ratio significantly below the industry average. The article discusses whether the market …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Market update Main company 🇺🇸 United States

Don't Ignore The Insider Selling In PTC Therapeutics

This article highlights recent insider selling at PTC Therapeutics (NASDAQ: PTCT), specifically noting that insiders sold shares worth US$1.4 million over the last year, with no purchases. Despite this, the company's market capitalization has increased, suggesting the insider selling might be opportunistic rather than …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Analyst action Main company 🇺🇸 United States

PTC Therapeutics, Inc. (PTCT) Stock Forecasts

PTC Therapeutics, Inc. (PTCT) has received a "HOLD" investment rating from Argus, with a target price lowered to $79.00 from a current price of $73.31. The report highlights medium subratings for industry, financial strength, and value, while management, safety, and growth subratings are low. …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Market update Main company 🇺🇸 United States

Have PTC Therapeutics Insiders Been Selling Stock?

PTC Therapeutics' CEO & Director, Matthew Klein, recently sold a portion of his shares for US$706k, reducing his holding by 6.2%. While this sale and an earlier one were below the current market price, indicating a potential negative signal, insiders still maintain significant ownership …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Zacks Research Downgrades PTC Therapeutics (NASDAQ:PTCT) to Hold

Zacks Research has downgraded PTC Therapeutics (NASDAQ:PTCT) from a "Strong Buy" to a "Hold" rating, despite the company's recent strong financial performance. PTC Therapeutics exceeded expectations in its latest quarterly results with an EPS of $0.92 and revenue of $360.52 million, a 101.5% year-over-year …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

PTC Therapeutics CEO Klein sells $705,722 in company stock

Matthew B. Klein, CEO of PTC Therapeutics, sold 10,292 shares of company stock for $705,722 to cover tax withholding obligations related to RSU vesting. Following the sale, Klein beneficially owns 383,868 shares. Analysts predict the company will be profitable in 2026, with recent Q2 …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

PTC Therapeutics (PTCT) CEO sells 10,292 shares to cover taxes

PTC Therapeutics CEO Matthew B. Klein sold 10,292 shares of common stock on August 4, 2026, at $68.57 per share to cover tax withholding obligations. This automatic "sell-to-cover" transaction was executed under a Rule 10b5-1 trading plan and was tied to the vesting of …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

PTC Therapeutics, Inc. $PTCT Stock Position Lifted by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in PTC Therapeutics (NASDAQ:PTCT) by 23.5% in the first quarter, now owning 84,320 shares. Several other major institutions, including Vanguard, Janus Henderson, and State Street, also expanded their positions in the biopharmaceutical company. Despite some insider …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Earnings Main company 🇺🇸 United States

Is It Too Late to Buy PTC Inc (PTC) After 5.9% Rally? GF Value Says Undervalued

PTC Inc. (PTC) shares recently rallied 5.9% but remain undervalued according to GuruFocus' GF Value, trading 33.3% below its estimated fair value of $221.47. The company's GF Score of 79/100 indicates above-average financial health and growth potential, despite low scores in valuation and momentum. …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Royal Bank of Canada Sells 19,561 Shares of PTC Inc. $PTC

Royal Bank of Canada has reduced its stake in PTC Inc. by selling 19,561 shares, retaining 142,735 shares valued at approximately $20.3 million. Despite a consensus "Hold" rating from analysts with an average price target of $170.14, PTC exceeded quarterly EPS expectations but missed …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Analyst action Main company 🇺🇸 United States

PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases

Analyst price targets for PTC Therapeutics (PTCT) are increasing, with several firms raising their targets due to strong Sephience performance and a promising broader pipeline. This has led to a slight increase in the fair value estimate for PTCT, although some analysts maintain a …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

PTCT Therapeutics (PTCT) insider to sell 10,292 vested shares under Rule 144

Matthew Klein, an insider at PTCT Therapeutics, has filed to sell 10,292 shares of common stock under Rule 144, valued at $705,754.35. These shares, which vested on August 3, 2026, were granted as compensation and are planned for sale on or after August 4, …

PTCT main company
Sharemaestro market context Trend signal active 52 weeks +41.8% PTCT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

The Manufacturers Life Insurance Company Cuts Position in PTC Inc. $PTC

The Manufacturers Life Insurance Company reduced its stake in PTC Inc. by 10.7% in the first quarter, selling 7,433 shares and now owning 62,223 shares valued at $8.87 million. Other institutional investors have also adjusted their positions in PTC, with hedge funds and institutional …

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketWatch Market update Main company 🇺🇸 United States

PTC Inc. stock rises Tuesday, still underperforms market

Shares of PTC Inc. (PTC) rose by 1.30% on Tuesday, closing at $141.68, marking its eighth consecutive day of gains. Despite this rise, the stock underperformed the broader market, as the S&P 500 Index and the Dow Jones Industrial Average both saw larger increases.

PTC main company
Sharemaestro market context Price above Trend Line 52 weeks -30.4% PTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context